Key result
High cytomegalovirus neutralizing antibody titers are linked to ~124% greater CAD risk.
Why the study?
Previous studies reported conflicting associations between CMV infection and CAD based on total anti-CMV antibodies, but levels of specific neutralising antibodies had not been evaluated.
Do high CMV-NA titres predict CAD occurrence and recurrent cardiac events better than total anti-CMV antibodies in an Asian Indian population?
Case-Control (n=782)
Do high CMV-NA titres predict CAD occurrence and recurrent cardiac events better than total anti-CMV antibodies in an Asian Indian population?
Odds Ratio: 2.24 (95% CI 1.31–3.85)
p-value: p=0.003
High CMV-NA titres, particularly in combination with inflammatory markers like sPLA2, are strongly associated with CAD occurrence and recurrent cardiac events in the Asian Indian population.
May support CMV-NA titres as CAD risk marker in Asian Indians; leaves open superiority over total antibodies and need for prospective validation.
BACKGROUND: Several studies have reported a conflicting association between cytomegalovirus (CMV) infection and coronary artery disease (CAD) based on the levels of total anti-CMV antibodies. However, none have estimated the levels of specific neutralising antibodies (NA) to CMV, which may be clinically more relevant. OBJECTIVE: To determine whether CMV-NA titres show a better association with CAD compared with total anti-CMV antibody levels. DESIGN: CMV-NA titres were measured by micro-neutralisation assay and anti-CMV IgG antibodies using ELISA in 391 consecutive CAD patients compared with the same number of controls (N=782), and 91 patients reporting recurrent cardiac events during a 4-year follow-up compared with those without a recurrent event (N=182). Levels of inflammatory markers, interleukin 6, high-sensitivity C reactive protein, fibrinogen and secretory phospholipase A2 (sPLA2), were measured by ELISA. Analysis of variance and logistic regression were used for statistical analyses. RESULTS: High CMV-NA titres showed a positive association with CAD occurrence (OR 2.24, 95% CI 1.31 to 3.85, p=0.003) and recurrent cardiac events in CAD patients (OR 4.65, 95% CI 1.21 to 17.86, p=0.025) compared with total CMV antibodies (OR 1.67, 95% CI 1.04 to 2.69, p=0.034, and 2.70, 1.04 to 7.02, p=0.040, respectively). Patients with higher quartile of CMV-NA titres and sPLA2 levels had an adjusted OR of 7.82 (95% CI 1.87 to 32.65, 0.005) for recurrent cardiac events compared with those with the lowest quartiles for both markers. CONCLUSION: These findings suggest that high CMV-NA titres in combination with inflammatory markers improve prediction of cardiac events in the Asian Indian population.
No takes yet. Share an insight, caveat, or question.
Mundkur et al. (2012) conducted a case-control in Coronary artery disease (n=782). High cytomegalovirus neutralising antibody (CMV-NA) titres vs. Low CMV-NA titres was evaluated on CAD occurrence (OR 2.24, 95% CI 1.31-3.85, p=0.003). High cytomegalovirus neutralising antibody titres were significantly associated with increased risk of coronary artery disease occurrence (OR 2.24; 95% CI 1.31-3.85; p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: